Home / NEWS LINE / Top 3 Healthcare Penny Stocks for 2017

Top 3 Healthcare Penny Stocks for 2017

The healthcare perseverance can be precarious for stocks of large companies, much less penny investments. Nevertheless, smaller companies that capture a niche can grow much faster than imposingly caps. That higher reward potential comes with principal risk. Of course, small-cap healthcare companies can be nudged out of the market by big contestants, and they can simply become unable to service debt when offerings and services don’t sell quickly enough. All of this makes the small-cap healthcare stalwarts on this schedule more attractive.

None of these are new companies – they have expand oned products and found the marketing outlets that are needed to sustain them. Because of the considerable risk, investors should continuously perform due diligence. It is important to mind for product failures, closing markets or excessive competition moving in. To learn more involving trading penny stocks, Investopedia Academy has a day trading course online.

Let’s look at how our top three picks be prostrated initiate down. All figures are current as of Dec. 10, 2017. (For a quick primer on healthcare fathers, check out: Investing in the Healthcare Sector.)

Curis, Inc. (CRIS)

Curis is plighted in biotechnology with a focus on developing drugs that treat cancers. It does critical amounts of research and collaborates with other drug makers in probe and developing drugs. Therefore, it must put drugs through trials and exist approvals, which means that the stock can fluctuate depending on the development for any given drug. Profits have been less than fruity while the company focuses on research. However, management says it is now likely to bring many drugs to market that will produce profits current forward.

Volatility for this stock is high, but that can be a good deed for investors who want to build a position by buying at support levels. The 50-day unfixed average is below the 200-day moving average, so cautious investors may scarcity to wait until the 50-day line is back on top before buying into this property. The company has negative operating income, as increasing research and development disbursements have negatively affected the bottom line. Investing in this farm animals must be based on whether investors see promise in the company’s drug imminent. (See also: Invest in Cancer Research With These 3 Stocks.) 

China Pharma Holdings, Inc. (CPHI)

China Pharma Holdings demonstrates and markets a broad range of products in China, targeting hospitals and retailers. The knock outs are focused on cardiovascular applications, brain diseases and infectious diseases. When the Chinese Theatre troupe reports results, it tends to have the majority of its assets as receivables, and investors should retain in mind that many companies do not collect all of their receivables.

The pile up dropped dramatically in May 2017, rebounded, then pulled back again. It is in a edgeways pattern now, perhaps forming a new base. Investors should note that the 50-day operating average has crossed below the 200-day moving average, which recommends that the stock could have more downside. However, these touching averages are trailing indicators. (See also: Pharma Majors to Benefit From China Opiate Inclusion.)

For the period ended March 31, 2017, the company reported that it had reset its losses. Operating income was negative but had rebounded dramatically from the antecedent quarter. Yearly revenues decreased by 23.5%. Revenues and income were also down in the age ended June 30, 2017. Investors who buy this stock are hoping for the rescue of effective and popular drugs. As with all penny drug stocks, purchasers of China Pharma Holdings shares must be willing to wait out fancy periods of volatility while hoping for profitability to return.

It is also material to remember that China monitors and controls companies closely, so any investor in this hackneyed is obtaining exposure to the geopolitical influences that could affect the bloodline. (For more, see: China on a Record High International Healthcare Acquisition Outing.)

  • Average Volume: 215,534
  • Market Cap: $7.409 million
  • P/E Ratio (TTM): -0.89
  • EPS (TTM): -$0.19

Repligen Corporation (RGEN)

Antibodies roast the product line for Repligen. The company sells worldwide and has been in trade since 1981. Quarterly revenues and operating income had been get up for several quarters, but both measures were down sequentially for the interval ending Sept. 30, 2017.

The stock price broke through resistance at on all sides of $34 per share in April 2017 and then climbed steadily, but it saw a run out of gas at the end of September, plummeting over 14% in one session on Sept. 26. Come what may, the company’s longevity offers stability. It is very unlikely that this comrades would disappear given its strong product line and marketing effectiveness. (See also: How to Pick Alluring Penny Stocks.)

  • Average Volume: 460,607
  • Market Cap: $1.549 billion
  • P/E Correspondence (TTM): 62.39
  • EPS (TTM): $0.57

The Bottom Line

Penny healthcare stocks are high risk. Flings of drugs can produce negative results, and the market may not readily accept a new treatment. On the other hand, a successful drug can cause a penny stock to hang and give investors profits they would not expect from numberless expensive stocks. It is wise to limit the percentage of your portfolio that you withhold in penny healthcare stocks – these are speculative plays. (See also: Treaty Penny Stocks’ Risks and Rewards.)

Check Also

Origination Fee Definition

What Is an Origination Fee? An origination fee is an upfront fee charged by a …

Leave a Reply

Your email address will not be published. Required fields are marked *